Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil prodrug transdermal - Corsair Pharma/United Therapeutics Corporation

Next Previous
Drug Profile

Treprostinil prodrug transdermal - Corsair Pharma/United Therapeutics Corporation

Alternative Names: CO-254; Transdermal treprostinil prodrug patch - United Therapeutics/Corsair Pharma; TRX-248; VPD-380

Latest Information Update: 08 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corsair Pharma
  • Developer Corsair Pharma; United Therapeutics Corporation
  • Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pulmonary arterial hypertension

Most Recent Events

  • 17 Mar 2025 Preclinical development is ongoing in USA (Transdermal, Patch)
  • 17 Mar 2025 Corsair Pharma plans a phase I trial for Pulmonary arterial hypertension (Transdermal), in the second quarter of 2025
  • 30 Jan 2018 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top